Personalized Pacemaker Heart Rate Settings for Heart Failure With Preserved Ejection Fraction
Tests personalized pacemaker settings in adults with heart failure and an existing pacemaker.
Plain-language title generated from the registry record
Registry title: PrEcision Pacing in HFpEF: the PEP-HFpEF Trial
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Tufts Medical CenterBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tufts Medical Center
- Trial code
- NCT07864558
- Record updated
- 10 November 2026
- Original description
The PEP-HFpEF study is a prospective, single-center mechanistic study evaluating personalized heart rate pacing (myPACE) in patients with heart failure with preserved ejection fraction (HFpEF) and existing cardiac physiologic pacemakers. Participants will undergo sequential periods of standard and personalized pacing with serial physiologic assessments to evaluate the effects of myPACE on exercise capacity, cardiac function, biomarkers, quality of life, and clinical outcomes.Read full original descriptionShow less
PrEcision Pacing in HFpEF: the PEP-HFpEF Trial
The PEP-HFpEF study is a prospective, single-center mechanistic study evaluating personalized heart rate pacing (myPACE) in patients with heart failure with preserved ejection fraction (HFpEF) and existing cardiac physiologic pacemakers. Participants will undergo sequential periods of standard and personalized pacing with serial physiologic assessments to evaluate the effects of myPACE on exercise capacity, cardiac function, biomarkers, quality of life, and clinical outcomes.
Inclusion: Age ≥18 years; Diagnosis of heart failure with preserved ejection fraction (HFpEF), defined as left ventricular ejection fraction (LVEF) ≥50% with symptoms and signs consistent with heart failure as determined by the treating investigator; New York Heart Association (NYHA) Class II or III symptoms despite stable, maximally tolerated guideline-directed medical therapy; Pre-existing FDA-approved cardiac physiologic pacemaker (e.g., conduction system pacing or cardiac resynchronization therapy) implanted for a standard clinical indication and capable of individualized lower-rate programming; Expected to require ongoing pacemaker therapy throughout the study period; Clinically stable at enrollment, without recent major changes in heart failure status that, in the opinion of the investigator, would interfere with interpretation of study outcomes; Able and willing to provide written informed consent; Able and willing to comply with all study procedures, including pacemaker programming, cardiopulmonary exercise testing (CPET), echocardiography, blood pressure measurements, autonomic testing, blood collection, and follow-up visits.
Exclusion: Any medical condition or life expectancy that, in the opinion of the investigator, would make participation unsafe or would substantially interfere with completion of the study or interpretation of study results; Left ventricular ejection fraction <50%; Age <18 years; Pregnancy, breastfeeding, or women of childbearing potential unwilling to use an acceptable method of contraception during study participation; Inability or unwillingness to provide informed consent; Inability to safely perform study procedures, including CPET or autonomic testing, in the opinion of the investigator; Enrollment in another interventional clinical trial that, in the opinion of the investigators, could interfere with this study or confound interpretation of the results; Prisoners, wards of the state, or other individuals for whom participation would not be permissible under applicable regulations or institutional policy.